George S Baillie

List of Publications by Year
in descending order

193 papers	12,388 citations	20797 60 h-index	30058 103 g-index
199 all docs	199 docs citations	199 times ranked	12122 citing authors

#	Article	IF	Citations
1	DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling. Science, 2005, 310, 1187-1191.	6.0	605
2	Targeting of Cyclic AMP Degradation to beta 2-Adrenergic Receptors by beta -Arrestins. Science, 2002, 298, 834-836.	6.0	476
3	Â-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates Â-adrenoceptor switching from Gs to Gi. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 940-945.	3.3	356
4	Sleep deprivation impairs cAMP signalling in the hippocampus. Nature, 2009, 461, 1122-1125.	13.7	339
5	Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. Journal of Antimicrobial Chemotherapy, 2000, 46, 397-403.	1.3	315
6	Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. Journal of Medical Microbiology, 2002, 51, 344-349.	0.7	310
7	cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System. Circulation Research, 2007, 100, 950-966.	2.0	283
8	The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO Journal, 1999, 18, 893-903.	3.5	269
9	Role of dimorphism in the development of Candida albicans biofilms. Journal of Medical Microbiology, 1999, 48, 671-679.	0.7	253
10	Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). British Journal of Pharmacology, 2002, 136, 421-433.	2.7	229
11	ERK2 Mitogen-activated Protein Kinase Binding, Phosphorylation, and Regulation of the PDE4D cAMP-specific Phosphodiesterases. Journal of Biological Chemistry, 2000, 275, 16609-16617.	1.6	215
12	A Complex between FAK, RACK1, and PDE4D5 Controls Spreading Initiation and Cancer Cell Polarity. Current Biology, 2010, 20, 1086-1092.	1.8	214
13	Therapeutic targeting of 3â€²,5â€²-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nature Reviews Drug Discovery, 2019, 18, 770-796.	21.5	205
14	Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS Journal, 2009, 276, 1790-1799.	2.2	192
15	Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1. ELife, 2016, 5, .	2.8	191
16	Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Letters, 2005, 579, 3264-3270.	1.3	186
17	RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with Î²Arrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the Î²2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells. Journal of Biological Chemistry, 2005, 280, 33178-33189.	1.6	185
18	Protein Kinase A Type I and Type II Define Distinct Intracellular Signaling Compartments. Circulation Research, 2008, 103, 836-844.	2.0	185

#	Article	IF	Citations
19	Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110Î³. Molecular Cell, 2011, 42, 84-95.	4.5	174
20	PGE1 stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. Journal of Cell Biology, 2006, 175, 441-451.	2.3	171
21	Production of extracellular matrix by Candida albicans biofilms. Journal of Medical Microbiology, 1998, 47, 253-256.	0.7	164
22	Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2. Journal of Biological Chemistry, 2003, 278, 33351-33363.	1.6	149
23	Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. British Journal of Pharmacology, 2000, 131, 811-819.	2.7	146
24	TAPAS-1, a Novel Microdomain within the Unique N-terminal Region of the PDE4A1 cAMP-specific Phosphodiesterase That Allows Rapid, Ca2+-triggered Membrane Association with Selectivity for Interaction with Phosphatidic Acid. Journal of Biological Chemistry, 2002, 277, 28298-28309.	1.6	145
25	Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, Î²-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochemical Journal, 2006, 398, 23-36.	1.7	144
26	Structure-Function Analysis of Core STRIPAK Proteins. Journal of Biological Chemistry, 2011, 286, 25065-25075.	1.6	136
27	Compartmentalization of cAMP-Dependent Signaling by Phosphodiesterase-4D Is Involved in the Regulation of Vasopressin-Mediated Water Reabsorption in Renal Principal Cells. Journal of the American Society of Nephrology: JASN, 2007, 18, 199-212.	3.0	134
28	TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling. Journal of Immunology, 2004, 173, 4847-4858.	0.4	123
29	Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Current Opinion in Cell Biology, 2005, 17, 129-134.	2.6	120
30	The Cardiac IKs Potassium Channel Macromolecular Complex Includes the Phosphodiesterase PDE4D3. Journal of Biological Chemistry, 2009, 284, 9140-9146.	1.6	118
31	p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. Journal of Cell Biology, 2007, 177, 1119-1132.	2.3	116
32	EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12791-12796.	3.3	109
33	Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2. Circulation Research, 2015, 117, 707-719.	2.0	105
34	Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species. Science Signaling, 2010, 3, ra20.	1.6	101
35	Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 287, L332-L343.	1.3	100
36	The Unique Amino-terminal Region of the PDE4D5 cAMP Phosphodiesterase Isoform Confers Preferential Interaction with Î²-Arrestins. Journal of Biological Chemistry, 2003, 278, 49230-49238.	1.6	97

#	Article	IF	Citations
37	Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)â€"HSP20 complex attenuates the Î²-agonist induced hypertrophic response in cardiac myocytes. Journal of Molecular and Cellular Cardiology, 2011, 50, 872-883.	0.9	94
38	The Structure of the Human RNase H2 Complex Defines Key Interaction Interfaces Relevant to Enzyme Function and Human Disease. Journal of Biological Chemistry, 2011, 286, 10530-10539.	1.6	94
39	Small Molecule AKAP-Protein Kinase A (PKA) Interaction Disruptors That Activate PKA Interfere with Compartmentalized cAMP Signaling in Cardiac Myocytes. Journal of Biological Chemistry, 2011, 286, 9079-9096.	1.6	92
40	Phosphorylation of RACK1 on Tyrosine 52 by c-Abl Is Required for Insulin-like Growth Factor I-mediated Regulation of Focal Adhesion Kinase. Journal of Biological Chemistry, 2009, 284, 20263-20274.	1.6	89
41	Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of Î²-arrestin using spot-immobilized peptide arrays. Biochemical Journal, 2007, 404, 71-80.	1.7	88
42	Iron-Limited Biofilms of Candida albicans and Their Susceptibility to Amphotericin B. Antimicrobial Agents and Chemotherapy, 1998, 42, 2146-2149.	1.4	87
43	Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7786-7791.	3.3	86
44	PDE2A2 regulates mitochondria morphology and apoptotic cell death via local modulation of cAMP/PKA signalling. ELife, 2017, 6, .	2.8	82
45	Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. British Journal of Pharmacology, 2004, 142, 339-351.	2.7	81
46	Cyclic AMP Phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a Vascular Endothelial Cadherin (VE-Cad)-based Signaling Complex and Controls cAMP-mediated Vascular Permeability. Journal of Biological Chemistry, 2010, 285, 33614-33622.	1.6	81
47	Amyloid Î² synaptotoxicity is Wntâ€PCP dependent and blocked by fasudil. Alzheimer's and Dementia, 2018, 14, 306-317.	0.4	81
48	Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Science Signaling, 2016, 9, ra109.	1.6	80
49	Interaction between integrin Î±5 and PDE4D regulates endothelial inflammatory signalling. Nature Cell Biology, 2016, 18, 1043-1053.	4.6	79
50	A high-fat diet promotes depression-like behavior in mice by suppressing hypothalamic PKA signaling. Translational Psychiatry, 2019, 9, 141.	2.4	77
51	The role and therapeutic targeting of Î±-, Î²- and Î³-secretase in Alzheimer's disease. Future Science OA, 2015, 1, FSO11.	0.9	75
52	A role for APP in Wnt signalling links synapse loss with Î²-amyloid production. Translational Psychiatry, 2018, 8, 179.	2.4	74
53	TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. Cancer Cell, 2017, 31, 621-634.e6.	7.7	73
54	Phorbol 12-myristate 13-acetate Triggers the Protein Kinase A-Mediated Phosphorylation and Activation of the PDE4D5 cAMP Phosphodiesterase in Human Aortic Smooth Muscle Cells through a Route Involving Extracellular Signal Regulated Kinase (ERK). Molecular Pharmacology, 2001, 60, 1100-1111.	1.0	71

#	Article	IF	Citations
55	Tyrosine 302 in RACK1 Is Essential for Insulin-like Growth Factor-I-mediated Competitive Binding of PP2A and Î²1 Integrin and for Tumor Cell Proliferation and Migration. Journal of Biological Chemistry, 2008, 283, 22952-22961.	1.6	67
56	The emerging role of HSP20 as a multifunctional protective agent. Cellular Signalling, 2011, 23, 1447-1454.	1.7	67
57	Î²-Arrestin 1 Inhibits the GTPase-Activating Protein Function of ARHGAP21, Promoting Activation of RhoA following Angiotensin II Type 1A Receptor Stimulation. Molecular and Cellular Biology, 2011, 31, 1066-1075.	1.1	67
58	PDE4B5, a Novel, Super-Short, Brain-Specific cAMP Phosphodiesterase-4 Variant Whose Isoform-Specifying N-Terminal Region Is Identical to That of cAMP Phosphodiesterase-4D6 (PDE4D6). Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 600-609.	1.3	65
59	MEK1 Binds Directly to Î²Arrestin1, Influencing Both Its Phosphorylation by ERK and the Timing of Its Isoprenaline-stimulated Internalization. Journal of Biological Chemistry, 2009, 284, 11425-11435.	1.6	65
60	Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. Biochemical Journal, 2011, 435, 755-769.	1.7	63
61	Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/Î²-Arrestin/cAMP Phosphodiesterase 4 Complex. Molecular and Cellular Biology, 2010, 30, 1660-1672.	1.1	61
62	Mdm2 Directs the Ubiquitination of Î²-Arrestin-sequestered cAMP Phosphodiesterase-4D5. Journal of Biological Chemistry, 2009, 284, 16170-16182.	1.6	59
63	cAMP: Novel concepts in compartmentalised signalling. Seminars in Cell and Developmental Biology, 2012, 23, 181-190.	2.3	59
64	Distinct functional outputs of PTEN signalling are controlled by dynamic association with Î²-arrestins. EMBO Journal, 2011, 30, 2557-2568.	3.5	58
65	Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. Cellular Signalling, 2014, 26, 2446-2459.	1.7	56
66	Gravin Orchestrates Protein Kinase A and Î²2-Adrenergic Receptor Signaling Critical for Synaptic Plasticity and Memory. Journal of Neuroscience, 2012, 32, 18137-18149.	1.7	54
67	PDE4-Mediated cAMP Signalling. Journal of Cardiovascular Development and Disease, 2018, 5, 8.	0.8	54
68	Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13320-13329.	3.3	54
69	1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, Î²arrestin and RACK1. Cellular Signalling, 2007, 19, 2612-2624.	1.7	53
70	Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition. Neuropsychopharmacology, 2016, 41, 1080-1092.	2.8	53
71	Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochemical Journal, 2003, 370, 429-438.	1.7	52
72	Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. European Journal of Cell Biology, 2006, 85, 673-678.	1.6	52

#	Article	IF	Citations
73	PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects. Biochemical Society Transactions, 2012, 40, 210-214.	1.6	52
74	Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory. Journal of Neuroscience, 2016, 36, 8936-8946.	1.7	52
75	Dynamic Regulation, Desensitization, and Cross-talk in Discrete Subcellular Microdomains during Î²2-Adrenoceptor and Prostanoid Receptor cAMP Signaling. Journal of Biological Chemistry, 2007, 282, 34235-34249.	1.6	51
76	The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagonâ€like peptideâ€1 release. British Journal of Pharmacology, 2009, 157, 633-644.	2.7	50
77	Compartmentalisation of second messenger signalling pathways. Current Opinion in Genetics and Development, 2014, 27, 20-25.	1.5	50
78	Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1533-42.	3.3	49
79	Specific interactions between Epac1, Î²-arrestin2 and PDE4D5 regulate Î²-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling. Cellular Signalling, 2013, 25, 970-980.	1.7	48
80	Targeting proteinâ€"protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. Future Medicinal Chemistry, 2013, 5, 451-464.	1.1	47
81	A Phosphodiesterase 3B-based Signaling Complex Integrates Exchange Protein Activated by cAMP 1 and Phosphatidylinositol 3-Kinase Signals in Human Arterial Endothelial Cells. Journal of Biological Chemistry, 2011, 286, 16285-16296.	1.6	46
82	The A-kinase-anchoring protein AKAP-Lbc facilitates cardioprotective PKA phosphorylation of Hsp20 on Ser16. Biochemical Journal, 2012, 446, 437-443.	1.7	42
83	Reciprocal regulation of PKA and Rac signaling. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8531-8536.	3.3	42
84	p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. Cell Reports, 2016, 14, 255-268.	2.9	42
85	Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cellular Signalling, 2008, 20, 2356-2369.	1.7	41
86	The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. British Journal of Cancer, 2014, 110, 1278-1287.	2.9	41
87	Mutations of Î²-arrestin 2 that limit self-association also interfere with interactions with the Î²2-adrenoceptor and the ERK1/2 MAPKs: implications for Î²2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochemical Journal, 2008, 413, 51-60.	1.7	40
88	cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling. Biochemical Society Transactions, 2007, 35, 938-941.	1.6	39
89	Molecular mechanism of GÎ±i activation by non-GPCR proteins with a GÎ±-Binding and Activating motif. Nature Communications, 2017, 8, 15163.	5.8	39
90	Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cellular Signalling, 2003, 15, 955-971.	1.7	37

#	Article	IF	Citations
91	p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. Cellular Signalling, 2010, 22, 1576-1596.	1.7	37
92	RACK(1) to the future â€“ a historical perspective. Cell Communication and Signaling, 2013, 11, 53.	2.7	37
93	Real-time probing of Î²-amyloid self-assembly and inhibition using fluorescence self-quenching between neighbouring dyes. Molecular BioSystems, 2014, 10, 34-44.	2.9	37
94	PKA phosphorylation of p62/SQSTM1 regulates PB1 domain interaction partner binding. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2765-2774.	1.9	37
95	AKAP95 Organizes a Nuclear Microdomain to Control Local cAMP for Regulating Nuclear PKA. Cell Chemical Biology, 2019, 26, 885-891.e4.	2.5	37
96	Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches. Biochemical Society Transactions, 2019, 47, 1557-1565.	1.6	36
97	Phosphodiesterase 4B: Master Regulator of Brain Signaling. Cells, 2020, 9, 1254.	1.8	36
98	Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293Î²2 cells and cardiac myocytes. Biochemical Journal, 2006, 394, 427-435.	1.7	35
99	Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochemical Journal, 2010, 428, 55-65.	1.7	35
100	Elucidation of a Structural Basis for the Inhibitor-Driven, p62 (SQSTM1)-Dependent Intracellular Redistribution of cAMP Phosphodiesterase-4A4 (PDE4A4). Journal of Medicinal Chemistry, 2011, 54, 3331-3347.	2.9	34
101	Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains. Cellular Signalling, 2015, 27, 756-769.	1.7	34
102	Î²-Arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of Î²2-adrenoceptor signalling to activation of ERK. Biochemical Society Transactions, 2005, 33, 1333.	1.6	33
103	cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. Biochemical Society Transactions, 2006, 34, 504-509.	1.6	33
104	Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression. Cellular Signalling, 2014, 26, 1958-1974.	1.7	33
105	Peptide array-based screening reveals a large number of proteins interacting with the ankyrin-repeat domain of the zDHHC17 S-acyltransferase. Journal of Biological Chemistry, 2017, 292, 17190-17202.	1.6	33
106	Ambra1 spatially regulates Src activity and Src/FAK-mediated cancer cell invasion via trafficking networks. ELife, 2017, 6, .	2.8	32
107	Dynamic Palmitoylation of the Sodium-Calcium Exchanger Modulates Its Structure, Affinity for Lipid-Ordered Domains, and Inhibition by XIP. Cell Reports, 2020, 31, 107697.	2.9	32
108	Cyclic AMPâ€specific phosphodiesterase, PDE8A1, is activated by protein kinase Aâ€mediated phosphorylation. FEBS Letters, 2012, 586, 1631-1637.	1.3	31

#	Article	IF	Citations
109	FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Molecular Psychiatry, 2018, 23, 1278-1286.	4.1	31
110	Targeted disruption of the heat shock protein 20â€“phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy. FEBS Open Bio, 2014, 4, 923-927.	1.0	30
111	UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy. Cellular Signalling, 2015, 27, 908-922.	1.7	29
112	Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C. Biochemical Journal, 2010, 432, 207-219.	1.7	28
113	Small heat shock protein 20 (Hsp20) facilitates nuclear import of protein kinase D 1 (PKD1) during cardiac hypertrophy. Cell Communication and Signaling, 2015, 13, 16.	2.7	28
114	Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners. Biochemical Journal, 2017, 474, 597-609.	1.7	27
115	Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change. Biochemical Journal, 2008, 411, 361-369.	1.7	26
116	Evolutionarily Conserved Role of Calcineurin in Phosphodegron-Dependent Degradation of Phosphodiesterase 4D. Molecular and Cellular Biology, 2010, 30, 4379-4390.	1.1	26
117	Missense mutation in DISC1 C-terminal coiled-coil has GSK3Î² signaling and sex-dependent behavioral effects in mice. Scientific Reports, 2016, 6, 18748.	1.6	26
118	Î²-Adrenergic modulation of myocardial conduction velocity: Connexins vs. sodium current. Journal of Molecular and Cellular Cardiology, 2014, 77, 147-154.	0.9	25
119	Interaction of suppressor of cytokine signalling 3 with cavin-1 links SOCS3 function and cavin-1 stability. Nature Communications, 2018, 9, 168.	5.8	25
120	Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochemical Journal, 2004, 380, 371-384.	1.7	24
121	A scanning peptide array approach uncovers association sites within the JNK/Î²arrestin signalling complex. FEBS Letters, 2009, 583, 3310-3316.	1.3	23
122	The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Science OA, 2021, 7, FSO650.	0.9	23
123	Epidermal Growth Factor Receptor substrate 8 (Eps8) controls Src/FAK-dependent phenotypes in squamous carcinoma cells. Journal of Cell Science, 2014, 127, 5303-16.	1.2	21
124	A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells. Nature Communications, 2014, 5, 4431.	5.8	21
125	Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. Oncotarget, 2016, 7, 70669-70684.	0.8	21
126	Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice. FEBS Letters, 2006, 580, 4126-4130.	1.3	20

#	Article	IF	Citations
127	Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression. British Journal of Cancer, 2015, 113, 1502-1511.	2.9	20
128	A biochemical and genetic discovery pipeline identifies PLCÎ´4b as a nonreceptor activator of heterotrimeric G-proteins. Journal of Biological Chemistry, 2018, 293, 16964-16983.	1.6	20
129	The phosphorylation of Hsp20 enhances its association with amyloid-Î² to increase protection against neuronal cell death. Molecular and Cellular Neurosciences, 2014, 61, 46-55.	1.0	19
130	PTEN controls glandular morphogenesis through a juxtamembrane Î²-Arrestin1/ARHGAP21 scaffolding complex. ELife, 2017, 6, .	2.8	19
131	The activity of cAMPâ€phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase Aâ€dependent phosphorylation within its unique Nâ€terminus. FEBS Letters, 2015, 589, 750-755.	1.3	18
132	RAB40C regulates RACK1 stability via the ubiquitinâ€"proteasome system. Future Science OA, 2018, 4, FSO317.	0.9	18
133	In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10). Cellular Signalling, 2008, 20, 2071-2083.	1.7	17
134	Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochemical Pharmacology, 2013, 85, 1297-1305.	2.0	17
135	The cardioprotective role of small heat-shock protein 20. Biochemical Society Transactions, 2014, 42, 270-273.	1.6	17
136	Protein kinase D in the hypertrophy pathway. Biochemical Society Transactions, 2012, 40, 287-289.	1.6	16
137	Effect of tacrolimus on skin microbiome in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1400-1406.	2.7	16
138	Post-translational regulation of cardiac myosin binding protein-C: A graphical review. Cellular Signalling, 2020, 76, 109788.	1.7	16
139	Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes. Biochemical Society Transactions, 2019, 47, 1405-1414.	1.6	16
140	Lanthanum-induced neurotoxicity: solving the riddle of its involvement in cognitive impairment?. Archives of Toxicology, 2013, 87, 2031-2035.	1.9	15
141	Phosphorylation of ezrin on Thr567 is required for the synergistic activation of cell spreading by EPAC1 and protein kinase A in HEK293T cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1749-1758.	1.9	15
142	Epidermal growth factor signaling through transient receptor potential melastatin 7 cation channel regulates vascular smooth muscle cell function. Clinical Science, 2020, 134, 2019-2035.	1.8	15
143	Epsteinâ€"Barr virus nuclear antigen 1 interacts with regulator of chromosome condensation 1 dynamically throughout the cell cycle. Journal of General Virology, 2017, 98, 251-265.	1.3	15
144	Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 2010, 38, 1058-1061.	1.6	14

#	Article	IF	Citations
145	Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling. Cellular Signalling, 2014, 26, 2573-2582.	1.7	14
146	Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A â€" C-Raf. BMC Cancer, 2019, 19, 266.	1.1	14
147	Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS. Anticancer Research, 2017, 37, 3833-3839.	0.5	14
148	Non-genetic therapeutic approaches to Canavan disease. Journal of the Neurological Sciences, 2016, 366, 116-124.	0.3	13
149	Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1â€"42â€mediated cytotoxicity. FEBS Open Bio, 2017, 7, 64-73.	1.0	13
150	The RanBP2/RanGAP1-SUMO complex gates Î²-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis. Oncogene, 2021, 40, 2243-2257.	2.6	13
151	Investigation of Extracellular Signal-Regulated Kinase 2 Mitogen-Activated Protein Kinase Phosphorylation and Regulation of Activity of PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterases. , 2005, 307, 225-238.		12
152	PDE8 controls CD4+ T cell motility through the PDE8A-Raf-1 kinase signaling complex. Cellular Signalling, 2017, 40, 62-72.	1.7	12
153	Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. European Urology Focus, 2018, 4, 376-384.	1.6	12
154	Can acetylcholinesterase activity be considered as a reliable biomarker for the assessment of cadmium-induced neurotoxicity?. Food and Chemical Toxicology, 2013, 56, 406-410.	1.8	11
155	Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins. Journal of Molecular and Cellular Cardiology, 2022, 165, 86-102.	0.9	11
156	Heat shock protein 20 (HSP20) is a novel substrate for protein kinase D1 (PKD1). Cell Biochemistry and Function, 2015, 33, 421-426.	1.4	10
157	The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer, 2018, 2018, 1-11.	0.4	10
158	Location, location, location: PDE4D5 function is directed by its unique N-terminal region. Cellular Signalling, 2016, 28, 701-705.	1.7	9
159	A769662 Inhibits Insulin-Stimulated Akt Activation in Human Macrovascular Endothelial Cells Independent of AMP-Activated Protein Kinase. International Journal of Molecular Sciences, 2018, 19, 3886.	1.8	9
160	Structural insights into TAZ2 domainâ€"mediated CBP/p300 recruitment by transactivation domain 1 of the lymphopoietic transcription factor E2A. Journal of Biological Chemistry, 2020, 295, 4303-4315.	1.6	9
161	The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumourâ€™s TMPRSS2-ERG Fusion Status. Prostate Cancer, 2019, 2019, 1-14.	0.4	8
162	Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 677-688.	3.3	8

#	Article	IF	Citations
163	Acetylcholinesterase activity as a neurotoxicity marker within the context of experimentally-simulated hyperprolinaemia: An in vitro approach. Journal of Natural Science, Biology and Medicine, 2015, 6, 98.	1.0	8
164	Phosphodiesterase-4 gates the ability of protein kinase A to phosphorylate G-protein receptor kinase-2 and influence its translocation. Biochemical Society Transactions, 2006, 34, 474-475.	1.6	7
165	RACK1 stabilises the activity of PP2A to regulate the transformed phenotype in mammary epithelial cells. Cellular Signalling, 2017, 35, 290-300.	1.7	7
166	Phosphorylation of PDE4A5 by MAPKAPK2 attenuates fibrin degradation via p75 signalling. Journal of Biochemistry, 2019, 166, 97-106.	0.9	7
167	Arrestin-Dependent Localization of Phosphodiesterases. Handbook of Experimental Pharmacology, 2014, 219, 293-307.	0.9	7
168	<i>Erythro</i>-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 2010, 432, 575-599.	1.7	6
169	Receptor dependent cellular uptake of synthetic low density lipoprotein by mammalian cells in serum-free tissue culture. Journal of Pharmacy and Pharmacology, 2010, 58, 1337-1342.	1.2	6
170	Increase in Ca2+ current by sustained cAMP levels enhances proliferation rate in GH3 cells. Life Sciences, 2018, 192, 144-150.	2.0	6
171	CMYA5 is a novel interaction partner of FHL2 in cardiac myocytes. FEBS Journal, 2022, 289, 4622-4645.	2.2	6
172	George Baillie on peptide array, a technique that transformed research on phosphodiesterases. Future Science OA, 2015, 1, FSO27.	0.9	4
173	SUMOylation of DISC1: A Potential Role in Neural Progenitor Proliferation in the Developing Cortex. Molecular Neuropsychiatry, 2016, 2, 20-27.	3.0	4
174	PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders. Cellular Signalling, 2019, 60, 31-38.	1.7	4
175	Mdm2 directs the ubiquitination of Î²-arrestin-sequestered cAMP phosphodiesterase-4D5.. Journal of Biological Chemistry, 2009, 284, 21776.	1.6	2
176	Cytodynamics and endpoint selection for a reliable in vitro assessment of nanoneurotoxicity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 407-408.	1.7	2
177	A High-fat Diet Promotes Depression-like Behavior in Mice by Suppressing Hypothalamic PKA Signaling. SSRN Electronic Journal, 0, , .	0.4	2
178	Investigation of Novel Cavin-1/Suppressor of CytokineÂSignaling 3 (SOCS3) Interactions by Coimmunoprecipitation, Peptide Pull-Down, and Peptide Array Overlay Approaches. Methods in Molecular Biology, 2020, 2169, 105-118.	0.4	2
179	<scp>SUMOylation</scp> does not affect cardiac troponin I stability but alters indirectly the development of force in response to Ca²⁺. FEBS Journal, 2022, 289, 6267-6285.	2.2	2
180	Perihaematomal cytokine expression is a crucial component of intracerebral haemorrhage pathophysiology. Neurological Sciences, 2014, 35, 1471-1473.	0.9	1

#	Article	IF	Citations
181	Editorial: Frontiers in the Pharmacological Manipulation of Intracellular cAMP Levels. Frontiers in Pharmacology, 2016, 7, 4.	1.6	1
182	Methods to Investigate Arrestins in Complex with Phosphodiesterases. Methods in Molecular Biology, 2019, 1957, 121-137.	0.4	1
183	Identification and Characterization of an Affimer Affinity Reagent for the Detection of the cAMP Sensor, EPAC1. Cells, 2021, 10, 2307.	1.8	1
184	Arrestin Regulation of Small GTPases. Handbook of Experimental Pharmacology, 2014, 219, 375-385.	0.9	1
185	Fibrin Breakdown Assay. Bio-protocol, 2020, 10, e3585.	0.2	1
186	Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 2021, 16, e0260283.	1.1	1
187	The extent and the nature of the cholinergic contribution to the hepatic encephalopathy-induced cognitive impairment. Free Radical Biology and Medicine, 2013, 65, 1516-1517.	1.3	0
188	3â€…Angiotensin 1â€"7 regulation of endothelin-1 system in pulmonary hypertension. Heart, 2015, 101, A1.3-A1.	1.2	0
189	Editorial. Cellular Signalling, 2016, 28, 699-700.	1.7	0
190	Cardiac cAMP Microdomains and Their Modulation Using Disruptor Peptides. Cardiac and Vascular Biology, 2017, , 161-173.	0.2	0
191	Modelling and mathematical analysis of the M$_{2}$ receptor-dependent joint signalling and secondary messenger network in CHO cells. Mathematical Medicine and Biology, 2018, 35, 279-297.	0.8	0
192	Cavinâ€1/PTRF as a new substrate of the SOCS3 E3 ubiquitin ligase complex. FASEB Journal, 2013, 27, 782.1.	0.2	0
193	Measuring cAMP Specific Phosphodiesterase Activity: A Two-step Radioassay. Bio-protocol, 2020, 10, e3581.	0.2	0